Humans Vary, So Cardiac Models Should Account for That Too!
暂无分享,去创建一个
[1] D. Noble. A modification of the Hodgkin—Huxley equations applicable to Purkinje fibre action and pacemaker potentials , 1962, The Journal of physiology.
[2] Blanca Rodríguez,et al. Impact of ionic current variability on human ventricular cellular electrophysiology. , 2009, American journal of physiology. Heart and circulatory physiology.
[3] N Parrott,et al. Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.
[4] M. Jamei,et al. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.
[5] Masoud Jamei,et al. Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance , 2016, Current Pharmacology Reports.
[6] Kairui Feng,et al. The Simcyp® Population-based ADME Simulator , 2009 .
[7] P. Mehler,et al. Dose‐Related Effects of Methadone on QT Prolongation in a Series of Patients with Torsade de Pointes , 2003, Pharmacotherapy.
[8] Leon Aarons,et al. Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data , 2015, British journal of clinical pharmacology.
[9] Kevin Burrage,et al. Variability in cardiac electrophysiology: Using experimentally-calibrated populations of models to move beyond the single virtual physiological human paradigm , 2016, Progress in biophysics and molecular biology.
[10] J. Karjalainen,et al. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. , 1994, Journal of the American College of Cardiology.
[11] E. Marder,et al. Multiple models to capture the variability in biological neurons and networks , 2011, Nature Neuroscience.
[12] E. Zaklyazminskaya,et al. Cardiac channelopathies: genetic and molecular mechanisms. , 2013, Gene.
[13] Yaning Wang,et al. Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions , 2011, Clinical pharmacokinetics.
[14] A. Baranchuk,et al. Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity , 2014, Therapeutic advances in infectious disease.
[15] Kevin Burrage,et al. In Vivo and In Silico Investigation Into Mechanisms of Frequency Dependence of Repolarization Alternans in Human Ventricular Cardiomyocytes , 2016, Circulation research.
[16] S. Visser,et al. Implementation of Quantitative and Systems Pharmacology in Large Pharma , 2014, CPT: pharmacometrics & systems pharmacology.
[17] N. Withofs,et al. Circadian rhythm of heart rate and heart rate variability , 2000, Archives of disease in childhood.
[18] M Sato,et al. Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective , 2017, CPT: pharmacometrics & systems pharmacology.
[19] Shiew-Mei Huang,et al. Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK , 2015, CPT: pharmacometrics & systems pharmacology.
[20] W. Bridson,et al. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. , 2008, Clinical therapeutics.
[21] CM Friedrich,et al. A model qualification method for mechanistic physiological QSP models to support model‐informed drug development , 2016, CPT: pharmacometrics & systems pharmacology.
[22] J. Weiss,et al. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. , 1996, Journal of the American College of Cardiology.
[23] J. Leeder,et al. Age Related Changes in Fractional Elimination Pathways for Drugs: Assessing the Impact of Variable Ontogeny on Metabolic Drug–Drug Interactions , 2013, Journal of clinical pharmacology.
[24] K H W J Ten Tusscher,et al. Cell model for efficient simulation of wave propagation in human ventricular tissue under normal and pathological conditions , 2006, Physics in medicine and biology.
[25] K. Sampson,et al. Molecular Pathophysiology of Congenital Long QT Syndrome. , 2017, Physiological reviews.
[26] S. Polak,et al. Virtual Clinical Trial Toward Polytherapy Safety Assessment: Combination of Physiologically Based Pharmacokinetic/Pharmacodynamic-Based Modeling and Simulation Approach With Drug-Drug Interactions Involving Terfenadine as an Example. , 2016, Journal of pharmaceutical sciences.
[27] S. Polak,et al. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials , 2016, BMC Pharmacology and Toxicology.
[28] N. Patel,et al. Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case study , 2013, Theoretical Biology and Medical Modelling.
[29] P W Macfarlane,et al. Effects of age, sex, and race on ECG interval measurements. , 1994, Journal of electrocardiology.
[30] Robert K. Amanfu,et al. Cardiac models in drug discovery and development: a review. , 2011, Critical reviews in biomedical engineering.
[31] E. Sobie. Parameter sensitivity analysis in electrophysiological models using multivariable regression. , 2009, Biophysical journal.
[32] M Jamei,et al. Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings. , 2012, Current drug metabolism.
[33] Yoram Rudy,et al. Simulation of the Undiseased Human Cardiac Ventricular Action Potential: Model Formulation and Experimental Validation , 2011, PLoS Comput. Biol..
[34] Ravi Iyengar,et al. Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic , 2011 .
[35] Sebastian Polak,et al. Inter-individual Variability in the Pre-clinical Drug Cardiotoxic Safety Assessment—Analysis of the Age–Cardiomyocytes Electric Capacitance Dependence , 2012, Journal of Cardiovascular Translational Research.
[36] J. Hancox,et al. Methadone, QTc interval prolongation and torsade de pointes: Case reports offer the best understanding of this problem , 2013, Therapeutic advances in psychopharmacology.
[37] Eric A. Sobie,et al. Regression Analysis for Constraining Free Parameters in Electrophysiological Models of Cardiac Cells , 2009, PLoS Comput. Biol..
[38] Gary R. Mirams,et al. Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing , 2012, British journal of pharmacology.
[39] J. Fahrenkrug,et al. Rhythmic 24-hour variations of frequently used clinical biochemical parameters in healthy young males – The Bispebjerg study of diurnal variations , 2012, Scandinavian journal of clinical and laboratory investigation.
[40] A. Baranchuk,et al. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports , 2013, Psychopharmacology.
[41] J. Vandenberghe,et al. Risk factors for QTc-prolongation: systematic review of the evidence , 2017, International Journal of Clinical Pharmacy.
[42] C. Clancy,et al. Computational approaches to understand cardiac electrophysiology and arrhythmias. , 2012, American journal of physiology. Heart and circulatory physiology.
[43] B. Rodríguez,et al. Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology , 2013, Proceedings of the National Academy of Sciences.
[44] Stefano Severi,et al. Mechanisms of pro-arrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy , 2016, Journal of molecular and cellular cardiology.
[45] A Rostami-Hodjegan,et al. Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making , 2015, CPT: pharmacometrics & systems pharmacology.
[46] Stefan A. Mann,et al. Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes. , 2016, Journal of molecular and cellular cardiology.
[47] S. Polak,et al. Serum potassium, sodium and calcium levels in healthy individuals - literature review and data analysis. , 2014, Folia medica Cracoviensia.
[48] Eric A Sobie,et al. Quantification of repolarization reserve to understand interpatient variability in the response to proarrhythmic drugs: a computational analysis. , 2011, Heart rhythm.
[49] C C Drovandi,et al. Sampling methods for exploring between-subject variability in cardiac electrophysiology experiments , 2016, Journal of The Royal Society Interface.
[50] Jingjing Yu,et al. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification , 2015, Drug Metabolism and Disposition.
[51] T. Teorell. STUDIES ON THE DIFFUSION EFFECT UPON IONIC DISTRIBUTION , 1937, The Journal of general physiology.
[52] G. Jensen,et al. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. , 2009, British journal of clinical pharmacology.
[53] M. Jerling,et al. Effect of renal impairment on multiple‐dose pharmacokinetics of extended‐release ranolazine , 2005, Clinical pharmacology and therapeutics.
[54] Kamil Fijorek,et al. Circadian Models of Serum Potassium, Sodium, and Calcium Concentrations in Healthy Individuals and Their Application to Cardiac Electrophysiology Simulations at Individual Level , 2013, Comput. Math. Methods Medicine.
[55] D. Wysowski,et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions , 2001, American Journal of Gastroenterology.
[56] E. Pueyo,et al. Experimentally-Based Computational Investigation into Beat-To-Beat Variability in Ventricular Repolarization and Its Response to Ionic Current Inhibition , 2016, PloS one.
[57] Henggui Zhang,et al. Cardiac cell modelling: observations from the heart of the cardiac physiome project. , 2011, Progress in biophysics and molecular biology.
[58] Gary R. Mirams,et al. Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment , 2013, Journal of pharmacological and toxicological methods.
[59] David G Strauss,et al. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias , 2017, Toxicological sciences : an official journal of the Society of Toxicology.
[60] B. Corrigan,et al. How Modeling and Simulation Have Enhanced Decision Making in New Drug Development , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[61] D. Noble. From the Hodgkin–Huxley axon to the virtual heart , 2007, The Journal of physiology.
[62] I Zineh,et al. Improving the tools of clinical pharmacology: Goals for 2017 and beyond , 2017, Clinical pharmacology and therapeutics.
[63] G. Gintant,et al. Evolution of strategies to improve preclinical cardiac safety testing , 2016, Nature Reviews Drug Discovery.
[64] L Zhang,et al. Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.
[65] M. Jamei,et al. Changes in Individual Drug-Independent System Parameters during Virtual Paediatric Pharmacokinetic Trials: Introducing Time-Varying Physiology into a Paediatric PBPK Model , 2014, The AAPS Journal.
[66] Ioannis P. Androulakis,et al. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine , 2016, Journal of Pharmacokinetics and Pharmacodynamics.
[67] Carlos Sánchez,et al. Inter-Subject Variability in Human Atrial Action Potential in Sinus Rhythm versus Chronic Atrial Fibrillation , 2014, PloS one.
[68] Eleonora Grandi,et al. Logistic regression analysis of populations of electrophysiological models to assess proarrythmic risk , 2016, MethodsX.
[69] Kelly C. Chang,et al. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel–Drug Binding Kinetics and Multichannel Pharmacology , 2017, Circulation. Arrhythmia and electrophysiology.
[70] A. Rostami-Hodjegan,et al. Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.
[71] Gary R. Mirams,et al. Uncertainty and variability in computational and mathematical models of cardiac physiology , 2016, The Journal of physiology.
[72] Shiew-Mei Huang,et al. The utility of modeling and simulation in drug development and regulatory review. , 2013, Journal of pharmaceutical sciences.
[73] W. Allan,et al. Long QT Syndrome , 1998, Pediatrics.
[74] Gary R. Mirams,et al. Recent developments in using mechanistic cardiac modelling for drug safety evaluation , 2016, Drug discovery today.
[75] A. Baranchuk,et al. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports , 2014, Therapeutic advances in psychopharmacology.
[76] Andreu M. Climent,et al. Balance between sodium and calcium currents underlying chronic atrial fibrillation termination: An in silico intersubject variability study , 2016, Heart rhythm.
[77] S. Polak,et al. Virtual population generator for human cardiomyocytes parameters: in silico drug cardiotoxicity assessment , 2012, Toxicology mechanisms and methods.
[78] Amrita X. Sarkar,et al. Exploiting mathematical models to illuminate electrophysiological variability between individuals , 2012, The Journal of physiology.
[79] M. Jamei,et al. Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information , 2014, CPT: pharmacometrics & systems pharmacology.
[80] A. Hodgkin,et al. A quantitative description of membrane current and its application to conduction and excitation in nerve , 1952, The Journal of physiology.
[81] J. Valentin. Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.
[82] S. Polak,et al. Model of the Distribution of Diastolic Left Ventricular Posterior Wall Thickness in Healthy Adults and Its Impact on the Behavior of a String of Virtual Cardiomyocytes , 2014, Journal of Cardiovascular Translational Research.
[83] A Nordmark,et al. Physiologically Based Models in Regulatory Submissions: Output From the ABPI/MHRA Forum on Physiologically Based Modeling and Simulation , 2015, CPT: pharmacometrics & systems pharmacology.
[84] Sebastian Polak,et al. An analysis of cardiomyocytes’ electrophysiology in the presence of the hERG gene mutations , 2013, Bio Algorithms Med Syst..
[85] Pras Pathmanathan,et al. Uncertainty and variability in models of the cardiac action potential: Can we build trustworthy models? , 2016, Journal of molecular and cellular cardiology.
[86] Kairui Feng,et al. The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.